Overview
Federico Cocozza practices practicing medicine in Paris, France.
His clinical expertise encompasses Triple-Negative Breast Cancer, T-Cell Lymphoma, and Non-Hodgkin Lymphoma.
He is actively involved in clinical research, co-authoring 9 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Federico Cocozza
Is Federico Cocozza a top-rated expert for Triple-Negative Breast Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Federico Cocozza is classified as an Experienced expert for Triple-Negative Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Federico Cocozza participate in research or clinical trials?
Yes. Federico Cocozza has published 9 articles and abstracts on conditions like Triple-Negative Breast Cancer. You can view a list of Federico Cocozza's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Non-Hodgkin LymphomaMr. Cocozza isExperienced. Learn about Non-Hodgkin Lymphoma.
- T-Cell LymphomaMr. Cocozza isExperienced. Learn about T-Cell Lymphoma.
- Triple-Negative Breast CancerMr. Cocozza isExperienced. Learn about Triple-Negative Breast Cancer.